Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy

Aims To Challenge Vyndaqel

 
• By Andrew McConaghie

After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.

Intellia HQ
It is still early days for its vivo gene-editing therapy NTLA-2001, but Intellia is accelerating its challenge Pfizer. • Source: Alamy

More from Business

More from Scrip